Mos3.1

Mos3.1 is a rationally designed, prefusion-stabilized, native-like HIV-1 envelope (Env) glycoprotein gp140 trimer. It was developed as part of the European AIDS Vaccine Initiative (EAVI2020) to address the significant global diversity of HIV-1. Unlike traditional immunogens based on a single viral isolate, Mos3.1 is a "mosaic" protein whose sequence is computationally optimized to include segments from various viral strains, thereby maximizing the coverage of potential T-cell and B-cell epitopes. In clinical experimental medicine studies, Mos3.1 is typically administered as a booster injection following a "consensus" Env prime (such as ConM or ConS) to focus the immune response toward conserved neutralizing epitopes and broaden the breadth of the elicited antibody repertoire.

Other names

mosaic gp140 Env trimermosaic HIV-1 Env immunogenMos3.1 gp140Mos-3.1 gp140Mos 3.1 gp140